Poseida Therapeutics

Poseida Therapeutics was a San Diego-based biotech focused on developing next-generation cell and gene therapies with its non-viral engineering platforms. Its core strategy centered on overcoming the limitations of viral vectors to create CAR-T products with a high proportion of stem cell memory T cells for enhanced persistence and potency. The company advanced a pipeline of autologous and allogeneic CAR-T candidates targeting hematological malignancies and solid tumors. Its significant technological achievements culminated in its acquisition by Roche in 2024, validating its platform and providing a path for accelerated development.

Proprietary non-viral gene engineering platforms including the piggyBac® DNA Modification System for high-efficiency gene delivery and the Cas-CLOVER™ high-fidelity gene editing system, focused on creating allogeneic cell therapies with a high percentage of stem cell memory T cells.

Competes in allogeneic CAR-T with firms like Allogene Therapeutics and CRISPR Therapeutics, and in target spaces with approved autologous CAR-Ts and bispecific antibodies. Differentiation lies in non-viral piggyBac® delivery (yielding high Tscm cells) and Cas-CLOVER gene editing. Roche's backing now provides a significant scale and resource advantage.